Related Experiment Video

Updated: Aug 19, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Cellular targets of gefitinib

Dirk Brehmer1, Zoltán Greff, Klaus Godl

  • 1Axxima Pharmaceuticals AG, Munich, Germany.

Cancer Research
|February 8, 2005
PubMed

Insights

Small molecule drugs targeting protein kinases are used in cancer therapy, but their selectivity is unclear. This study used proteomics to identify gefitinib

Area of Science:

  • Oncology
  • Pharmacology
  • Proteomics

Background:

  • Targeted inhibition of protein kinases using small molecule drugs represents a significant advancement in anticancer therapy.
  • The precise selectivity and cellular targets of these therapeutic agents, such as gefitinib, remain incompletely understood.
  • Understanding drug selectivity is crucial for optimizing efficacy and minimizing off-target effects in cancer treatment.

Purpose of the Study:

  • To investigate the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor, gefitinib.
  • To elucidate the selectivity profile of gefitinib beyond its known target.
  • To identify alternative cellular mechanisms of action for gefitinib.

Main Methods:

  • Utilized a proteomic approach to comprehensively profile the cellular targets of gefitinib.
  • Applied mass spectrometry-based techniques for unbiased target identification.
  • Analyzed gefitinib's interactions within the cellular proteome.

Main Results:

  • Identified multiple cellular targets of gefitinib, suggesting broader activity than previously recognized.
  • Revealed potential off-target effects and alternative pathways influenced by gefitinib.
  • The proteomic data provides a detailed map of gefitinib's cellular interactions.

Conclusions:

  • Gefitinib exhibits alternative cellular modes of action beyond direct epidermal growth factor receptor inhibition.
  • The findings challenge the assumption of high selectivity for gefitinib and similar kinase inhibitors.
  • This research provides a rationale for developing new drugs with improved selectivity and efficacy profiles.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: